JP2004526756A - ｈＹＡＫ１及びｈＹＡＫ３キナーゼのキノリン阻害剤 - Google Patents

ｈＹＡＫ１及びｈＹＡＫ３キナーゼのキノリン阻害剤 Download PDF

Info

Publication number
JP2004526756A
JP2004526756A JP2002580090A JP2002580090A JP2004526756A JP 2004526756 A JP2004526756 A JP 2004526756A JP 2002580090 A JP2002580090 A JP 2002580090A JP 2002580090 A JP2002580090 A JP 2002580090A JP 2004526756 A JP2004526756 A JP 2004526756A
Authority
JP
Japan
Prior art keywords
quinoline
methoxy
carboxylic acid
phenylamino
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002580090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004526756A5 (enExample
Inventor
ブライアン，デボラ，エル．
バーゲス，ジョエル，エル．
キャラハン，ジェームズ，エフ．
Original Assignee
スミスクライン ビーチャム コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スミスクライン ビーチャム コーポレーション filed Critical スミスクライン ビーチャム コーポレーション
Publication of JP2004526756A publication Critical patent/JP2004526756A/ja
Publication of JP2004526756A5 publication Critical patent/JP2004526756A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
JP2002580090A 2001-04-06 2002-04-04 ｈＹＡＫ１及びｈＹＡＫ３キナーゼのキノリン阻害剤 Pending JP2004526756A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28222901P 2001-04-06 2001-04-06
PCT/US2002/010657 WO2002081728A2 (en) 2001-04-06 2002-04-04 Quinoline inhibitors of hyak1 and hyak3 kinases

Publications (2)

Publication Number Publication Date
JP2004526756A true JP2004526756A (ja) 2004-09-02
JP2004526756A5 JP2004526756A5 (enExample) 2006-01-05

Family

ID=23080586

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002580090A Pending JP2004526756A (ja) 2001-04-06 2002-04-04 ｈＹＡＫ１及びｈＹＡＫ３キナーゼのキノリン阻害剤

Country Status (5)

Country Link
US (1) US7087758B2 (enExample)
EP (1) EP1372654A4 (enExample)
JP (1) JP2004526756A (enExample)
AU (1) AU2002256085A1 (enExample)
WO (1) WO2002081728A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503094A (ja) * 2002-10-16 2006-01-26 スミスクライン ビーチャム コーポレーション 化合物
JP2009510113A (ja) * 2005-09-30 2009-03-12 ブリストル−マイヤーズ スクイブ カンパニー Ｍｅｔキナーゼインヒビター
JP2012520249A (ja) * 2009-03-12 2012-09-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３モジュレータとしての置換された２−メルカプトキノリン−３−カルボキサミド

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100453946B1 (ko) * 2002-10-11 2004-10-20 (주) 비엔씨바이오팜 6-메틸피리딘 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
EP1718297A4 (en) * 2004-01-09 2009-09-02 Smithkline Beecham Corp NEW CHEMICAL COMPOUNDS
AR053602A1 (es) * 2005-05-03 2007-05-09 Smithkline Beecham Corp Compuesto de 2- arilamino -4-oxo-1,3-tiazol-5(4h)- substituido, composicion farmaceutica que lo comprende, proceso para prepararla y uso del compuesto para preparar un medicamento
PE20070083A1 (es) * 2005-06-08 2007-01-27 Smithkline Beecham Corp (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona
US8106071B2 (en) * 2007-02-21 2012-01-31 Biobud Co., Ltd. Compositions for treating hyperproliferative vascular disorders and cancers
US20100286041A1 (en) * 2007-03-22 2010-11-11 Smithkline Beecham Corporation (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
WO2009001224A2 (en) 2007-06-22 2008-12-31 Eth Zurich Antivirals
TWI504395B (zh) 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
TW201038565A (en) 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
CA2809287C (en) 2010-08-27 2018-05-22 Gruenenthal Gmbh Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators
WO2012025237A1 (en) 2010-08-27 2012-03-01 Grünenthal GmbH Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators
PT2609083E (pt) 2010-08-27 2015-07-01 Gruenenthal Gmbh 2-oxi-quinolina-3-carboxamidas substituídas como moduladores de kcnq2/3
EP2611780A1 (en) 2010-09-01 2013-07-10 Grünenthal GmbH Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as kcnq2/3 modulators
US12012394B2 (en) 2018-02-19 2024-06-18 Washington University Alpha-synuclein ligands
JP2025529185A (ja) * 2022-08-30 2025-09-04 パンネックス セラピューティクス インコーポレイテッド パネキシン－１調節剤及びパネキシン－１が関与する疾患の治療方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3210063A1 (de) * 1982-03-19 1983-09-22 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
PT79699B (en) * 1983-12-22 1986-12-10 Pfizer Process for preparing quinolone inotropic agents
GB8727737D0 (en) 1987-11-26 1987-12-31 Ici Plc Antitumour agents
WO1996028444A1 (en) 1995-03-15 1996-09-19 Pfizer Inc. 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS
US6342514B1 (en) * 1996-10-23 2002-01-29 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6225329B1 (en) 1998-03-12 2001-05-01 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
EP1147094A1 (en) * 1999-01-15 2001-10-24 Novo Nordisk A/S Non-peptide glp-1 agonists
JP2000309585A (ja) * 1999-02-26 2000-11-07 Kyorin Pharmaceut Co Ltd ６−置換ヘテロキノリンカルボン酸誘導体とその付加塩及びそれらの製造方法
GB0109103D0 (en) * 2001-04-11 2001-05-30 Pfizer Ltd Novel compounds

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503094A (ja) * 2002-10-16 2006-01-26 スミスクライン ビーチャム コーポレーション 化合物
JP2009510113A (ja) * 2005-09-30 2009-03-12 ブリストル−マイヤーズ スクイブ カンパニー Ｍｅｔキナーゼインヒビター
JP2012520249A (ja) * 2009-03-12 2012-09-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３モジュレータとしての置換された２−メルカプトキノリン−３−カルボキサミド

Also Published As

Publication number Publication date
WO2002081728A3 (en) 2002-11-21
WO2002081728A2 (en) 2002-10-17
EP1372654A2 (en) 2004-01-02
EP1372654A4 (en) 2007-10-03
AU2002256085A1 (en) 2002-10-21
US20050043352A1 (en) 2005-02-24
US7087758B2 (en) 2006-08-08

Similar Documents

Publication Publication Date Title
JP2004526756A (ja) ｈＹＡＫ１及びｈＹＡＫ３キナーゼのキノリン阻害剤
JP7738910B2 (ja) 置換ピリダジン化合物
CN100475796C (zh) 作为大麻素受体调制剂的噻唑衍生物
JP5235887B2 (ja) Ｒｈｏキナーゼ阻害剤
KR100628285B1 (ko) 사이토킨 억제제로서 유용한 아미드 유도체
JP6663866B2 (ja) リジン特異的なデメチラーゼ−１の阻害剤
US20070232681A1 (en) Compounds Having Crth2 Antagonist Activity
CN104837490B (zh) 作为无义突变抑制子的嘧啶并[4，5‑b]喹啉‑4，5(3H，10H)‑二酮
JP2002501532A (ja) 新規血管形成阻害薬
US20090226377A1 (en) Novel sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors
MXPA01000895A (es) Derivados de amida utiles como inhibidores de la produccion de citocinas.
EA006300B1 (ru) Производные фталазинона
JP2010501593A (ja) イソキノリン、キナゾリンおよびフタラジン誘導体
JP2002525358A (ja) ベンズアミド誘導体及びサイトカイン阻害剤としてのその使用
JP2010506851A (ja) 二環式ヘテロ芳香族化合物
JP2009541241A (ja) オキソ置換イミダゾ［１，２ｂ］ピリダジン、その調製方法、及び医薬としての使用
BR112020020008A2 (pt) Sais mono ácido de 6-aminoisoquinolinas e seus usos
JP2011507850A (ja) Ｒｈｏキナーゼインヒビターとしてのアニリドおよびアナログ
WO2014207213A1 (en) Novel inhibitors of protein kinase c epsilon signaling
KR20150118152A (ko) 키나제 억제제로서의 퀴나졸린
Feng et al. Structure-based design and characterization of the highly potent and selective covalent inhibitors targeting the lysine methyltransferases G9a/GLP
JP2010522226A (ja) 酵素ｐｄｅ７及び／又はｐｄｅ４の二重阻害化合物、薬剤組成物および利用法
JP2016185947A (ja) ＩＲＥ−１αインヒビター
TW201625610A (zh) 萘啶二酮（ｎａｐｈｔｈｙｒｉｄｉｎｅｄｉｏｎｅ）衍生物
KR102374033B1 (ko) 특정 단백질 키나제 억제제

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090609